The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Community-based Cluster Randomized Controlled Trial In Rural Bangladesh To Evaluate The Impact Of The Use Of Iron/folic Acid Supplements Early In Pregnancy On The Risk Of Neonatal MortalityBACKGROUND An Effective Program Of Antenatal Iron/folic Ac
Funder
National Health and Medical Research Council
Funding Amount
$2,564,922.00
Summary
This community-based trial in rural Bangladesh will determine if iron/folic acid supplementation commencing in the first trimester of pregnancy significantly reduces newborn deaths, and whether this approach is cost-effective. This trial has the potential to inform international public health policy about the importance of starting antenatal iron/folic acid supplementation early to improve neonatal survival, and to help countries reach their child survival Millennium Development Goal
Methylation As A Risk And Prognostic Factor For Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$594,913.00
Summary
DNA methylation is a process playing critical roles throughout life by altering the expression of genes. This study aims to investigate the potential use of methylation as marker of risk and early diagnosis of breast cancer in women with no clinical evidence of disease and marker of prognosis and response to treatment in breast cancer cases.
Statistical Analysis Of An International 10 Year Prospective Family Study Of Gene-environment Interactions On Risk Of Female Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$450,198.00
Summary
This study will provide new and credible information on how the effects of environmental and lifestyle factors on breast cancer risk depend on a woman's underlying genetic susceptibility using a large, international 10 year prospective family study.
IMPROVE - Investigating Medication Re-Purposing To Reduce Risk Of OVarian Cancer And Extend Survival
Funder
National Health and Medical Research Council
Funding Amount
$430,196.00
Summary
Ovarian cancer is the 6th most common cause of cancer death in women and the proportion of women who die from their disease has not improved substantially over time. This large-scale study will use de-identified data from the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index to investigate whether medications commonly used for other conditions can help decrease the risk of ovarian cancer developing or improve survival from ovarian cancer after diagnosis.
The Ovarian Cancer Prognosis And Lifestyle (OPAL) Study: Long-term Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$871,657.00
Summary
Ovarian cancer affects 1500 women each year in Australia and 5-year survival is <45%. Affected women thus face a poor prognosis and often ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study is following 960 women with ovarian cancer to identify whether lifestyle is associated with long-term survival to provide evidence for women with this disease.
Improving Outcomes From Ovarian Cancer: Building The Evidence To Help Women Help Themselves
Funder
National Health and Medical Research Council
Funding Amount
$1,839,772.00
Summary
Ovarian cancer affects 1300 women each year in Australia and 5-year survival is <45%. Women with this cancer thus face a poor prognosis and many ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study will follow 1200 women with ovarian cancer to identify whether lifestyle is associated with survival to provide guidance for women with this disease.
Determining The Natural History Of Localized High-risk Melanoma And Risk Factors For Melanoma Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$103,980.00
Summary
This PhD thesis aims to describe 2-year survival rates of patients with localised melanoma. We will investigate risk factors and patterns of melanoma spread in patients with high-risk localised lesions. Risk factors for developing ulcerated versus non-ulcerated melanomas will be explored. We aim to describe support service use in melanoma patients in rural, regional and urban areas in Queensland.
Risk Of Recurrence After Diagnosis Of Invasive Breast Cancer By Molecular Subtype As Defined By ER, PR And Her2 Status
Funder
National Health and Medical Research Council
Funding Amount
$500,622.00
Summary
Breast cancer is a heterogeneous disease. Molecular subtypes have been identified that differ in terms of prognosis and response to treatment. This study aims to estimate recurrence free survival of breast cancer by molecular subtypes in a population-based sample of Australian women. The results will assist clinicians to guide their therapeutic decisions and will inform women about their anticipated outcome after diagnosis of breast cancer.
Ovarian and endometrial cancer affect >3,200 women each year in Australia and 3 or 4 women die from these cancers every day. The overall aim of my program of research is to reduce the burden of these cancers in future generations of Australian women by increasing our understanding of (i) what causes them, (ii) how we can optimise patient management to enhance patient outcomes and (ii) how lifestyle changes might improve quality and life and survival, for women who are diagnosed with them.
Who To Treat, When To Treat And How To Treat Prostate Cancer: Generating Evidence To Guide Prostate Cancer Treatment Decisions
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
There is considerable uncertainty about which treatments lead to better outcomes for men with prostate cancer and whether treatment is always necessary. This project will compare different treatment options for prostate cancer, including active surveillance, to determine which offers the best chance of survival and least harm to men’s physical and mental wellbeing. It will also explore whether some men who do not receive active treatment (healthy older men) would benefit if they did.